AU6968301A - Small technetium-99m and rhenium labeled agents and methods for imaging tumors - Google Patents

Small technetium-99m and rhenium labeled agents and methods for imaging tumors

Info

Publication number
AU6968301A
AU6968301A AU6968301A AU6968301A AU6968301A AU 6968301 A AU6968301 A AU 6968301A AU 6968301 A AU6968301 A AU 6968301A AU 6968301 A AU6968301 A AU 6968301A AU 6968301 A AU6968301 A AU 6968301A
Authority
AU
Australia
Prior art keywords
technetium
tumors
complexes
methods
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU6968301A
Other languages
English (en)
Inventor
Ashfaq Mahmood
Matthais Friebe
Christina Bolzati
Alun G Jones
Alan Davison
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Harvard University
Original Assignee
Massachusetts Institute of Technology
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology, Harvard University filed Critical Massachusetts Institute of Technology
Publication of AU6968301A publication Critical patent/AU6968301A/xx
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU6968301A 2000-04-28 2001-04-27 Small technetium-99m and rhenium labeled agents and methods for imaging tumors Pending AU6968301A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20063300P 2000-04-28 2000-04-28
PCT/US2001/013550 WO2001083436A2 (en) 2000-04-28 2001-04-27 Small technetium-99m and rhenium labeled agents and methods for imaging tumors

Publications (1)

Publication Number Publication Date
AU6968301A true AU6968301A (en) 2001-11-12

Family

ID=22742530

Family Applications (2)

Application Number Title Priority Date Filing Date
AU6968301A Pending AU6968301A (en) 2000-04-28 2001-04-27 Small technetium-99m and rhenium labeled agents and methods for imaging tumors
AU2001269683A Ceased AU2001269683B2 (en) 2000-04-28 2001-04-27 Small technetium-99m and rhenium labeled agents and methods for imaging tumors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001269683A Ceased AU2001269683B2 (en) 2000-04-28 2001-04-27 Small technetium-99m and rhenium labeled agents and methods for imaging tumors

Country Status (8)

Country Link
US (2) US7321027B2 (enExample)
EP (1) EP1276718B1 (enExample)
JP (1) JP5186075B2 (enExample)
AT (1) ATE359998T1 (enExample)
AU (2) AU6968301A (enExample)
CA (1) CA2407592C (enExample)
DE (1) DE60127951T2 (enExample)
WO (1) WO2001083436A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515131B2 (en) 2000-02-22 2003-02-04 Biostream Therapeutics, Inc. Imagining agents for diagnosis of Parkinson's disease
US20060159617A1 (en) * 2002-11-08 2006-07-20 Ashfaq Mahmood Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors
JP2009051784A (ja) * 2007-08-28 2009-03-12 Inst Nuclear Energy Research Rocaec 癌を抑制する放射性物質及びその調整方法
WO2010144891A1 (en) * 2009-06-13 2010-12-16 President And Fellows Of Harvard College Compositions and methods for imaging tissues, organs and tumors
US10550139B2 (en) 2014-06-09 2020-02-04 Triad National Security, Llc Polydentate ligands and their complexes for molecular catalysis
WO2015191505A1 (en) * 2014-06-09 2015-12-17 Los Alamos National Security, Llc Polydentate ligands and their complexes for molecular catalysis
US9850183B2 (en) 2014-06-27 2017-12-26 Reiley Pharmaceuticals, Inc. Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging
EP3693022A3 (en) 2015-01-09 2020-09-16 Reiley Pharmaceuticals, Inc. Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
US10729669B2 (en) 2015-07-28 2020-08-04 University Of Iowa Research Foundation Compositions and methods for treating cancer
AU2017281940C1 (en) 2016-06-24 2024-11-07 University Of Iowa Research Foundation Compositions and methods of treating melanoma
WO2017223428A1 (en) 2016-06-24 2017-12-28 Cornell University Rhenium complexes and methods of use for treating cancer
US10487100B1 (en) 2017-04-04 2019-11-26 Triad National Security, Llc Macrocyclic ligands and their complexes for bifunctional molecular catalysis
US11529335B2 (en) 2020-07-31 2022-12-20 University Of Iowa Research Foundation Compositions and methods for treating cancer
WO2023009442A1 (en) * 2021-07-26 2023-02-02 Rapid Therapeutic Sciences Laboratories, Inc. Improved process for ph-balanced cbg (# 10)
CN120647688A (zh) * 2024-03-15 2025-09-16 中国科学院上海药物研究所 一种黑色素瘤靶向的放射性药物及其制备与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA852981B (en) * 1984-04-30 1985-11-27 Univ Johns Hopkins Brain imaging radiopharmaceuticals
US4638051A (en) * 1984-04-30 1987-01-20 The Johns Hopkins University Brain imaging radiopharmaceuticals
US5136038A (en) * 1984-07-19 1992-08-04 University Of Florida Radiopharmaceuticals and chelating agents useful in their preparation
ZA863205B (en) * 1985-05-01 1987-08-26 Univ New York State Res Found Diagnostic radiopharmaceutical compounds
JPH02180865A (ja) * 1987-12-29 1990-07-13 Nippon Mejifuijitsukusu Kk キレート形成性化合物とその用途
EP0381713B1 (en) * 1988-04-29 1994-01-19 Mallinckrodt, Inc. Diaminedithiol chelating agents for radiopharmaceuticals
US5919934A (en) * 1997-02-19 1999-07-06 The George Washington University Compounds, compositions, and methods for cancer imaging and therapy

Also Published As

Publication number Publication date
US20080226550A1 (en) 2008-09-18
WO2001083436A2 (en) 2001-11-08
ATE359998T1 (de) 2007-05-15
EP1276718B1 (en) 2007-04-18
US20040097735A1 (en) 2004-05-20
EP1276718A2 (en) 2003-01-22
JP2004501093A (ja) 2004-01-15
WO2001083436A3 (en) 2002-06-20
CA2407592C (en) 2011-03-22
DE60127951D1 (de) 2007-05-31
CA2407592A1 (en) 2001-11-08
DE60127951T2 (de) 2008-01-17
JP5186075B2 (ja) 2013-04-17
US7321027B2 (en) 2008-01-22
AU2001269683B2 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
ATE359998T1 (de) Kleine technetium-99m und rhenium markierte mittel und verfahren zum tumor-imaging
Price et al. H4octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy
Vaughn et al. Chelation with a twist: a bifunctional chelator to enable room temperature radiolabeling and targeted PET imaging with scandium-44
Kiess et al. Prostate-specific membrane antigen as a target for cancer imaging and therapy
Mansi et al. Bombesin-targeted PET of prostate cancer
PT1472541E (pt) Agentes de imagiologia e métodos de imagiologia de naaladase de psma
Kang et al. Synthesis and preclinical evaluation of bifunctional ligands for improved chelation chemistry of 90Y and 177Lu for targeted radioimmunotherapy
Yazdani et al. A bone-seeking trans-cyclooctene for pretargeting and bioorthogonal chemistry: a proof of concept study using 99mTc-and 177Lu-labeled tetrazines
Smith-Jones et al. Antibody labeling with copper-67 using the bifunctional macrocycle 4-[(1, 4, 8, 11-tetraazacyclotetradec-1-yl) methyl] benzoic acid
Nichols et al. 68Ga chelating bioorthogonal tetrazine polymers for the multistep labeling of cancer biomarkers
JPH05504973A (ja) 二官能性dtpa型リガンド
WO2008045604A3 (en) Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
WO2002087498A3 (en) Diagnostic imaging compositions, their methods of synthesis and use
Melis et al. Bifunctional chelators for radiorhenium: Past, present and future outlook
WO2020186328A1 (en) Chelators and methods of making and using same
IL131386A0 (en) Method for the detection and localization of malignant human tumours
CA3027920C (en) Modified dextran conjugates comprising a lysine-urea-glutamate pharmacophore
Mojarrad et al. Novel radiopharmaceutical (Technetium-99m)-(DOTA-NHS-ester)-Methionine as a SPECT-CT tumor imaging agent
Shukla et al. Dimercaptosuccinic acid: a multifunctional cost effective agent for imaging and therapy
IL175667A (en) Imaging agent which comrises a synthetic caspase-3 inhibitor labeled with an imaging moiety, a radiopharmaceutical composition comprising the same, a kit for the preparation of said composition and a method of diagnosis based thereon
Salih et al. DFO-Km: a modular chelator as a new chemical tool for the construction of zirconium-89-based radiopharmaceuticals
Frindel et al. Cyclam te1pa for 64Cu PET imaging. Bioconjugation to antibody, radiolabeling and preclinical application in xenografted colorectal cancer
ATE298757T1 (de) Ternärligand-komplexe verwendbar als radiopharmazeutika
WO2004043380A8 (en) Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors
Zhang et al. Targeting hypoxia in tumors using 2-nitroimidazoles with peptidic chelators for technetium-99m: effect of lipophilicity